SLC5A2 and chronic kidney disease: In CKD patients without type 2 diabetes, it is recommended to start an SGLT2 inhibitor in case of an eGFR at least 20 ml/min/1.73 m2 with a UACR at least 200 mg/g (20 mg/mmol) or heart failure, irrespective of the UACR.